UNAIDS and UNFPA launch road map to stop new HIV infections
1306  

UNAIDS and UNFPA launch road map to stop new HIV infections

Global HIV Prevention Coalition holds first meeting in Geneva, Switzerland, to find ways to strengthen and sustain political commitment for HIV prevention As part of global efforts to end AIDS as a public health threat, UNAIDS, the United Nations Population Fund (UNFPA) and partners have launched ...

October 12, 2017
News  
Innovative HIV Treatment Becomes Accessible All over the World
1226  

Innovative HIV Treatment Becomes Accessible All over the World

The World Heath Organization and UNAIDS have announced approval of a revolutionary pricing agreement that will facilitate access to the first affordable and all-purpose single-pill HIV regimen including Dolutegravir (DTG) for the public sector in low and middle-income countries. Its price will be around 75 ...

October 02, 2017
ECUO  News  
European Commission Approves Symtuza® for the Treatment of HIV-1 In Adults and Adolescents in Europe
1406  

European Commission Approves Symtuza® for the Treatment of HIV-1 In Adults and Adolescents in Europe

Janssen-Cilag International NV (Janssen) today announced that the European Commission has approved the use of Symtuza® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single-tablet regimen (STR), for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with ...

September 27, 2017
News  
Sanofi Tests Three-in-one Antibody to Treat or Prevent HIV
1318  

Sanofi Tests Three-in-one Antibody to Treat or Prevent HIV

A three-pronged man-made antibody, created by French drugmaker Sanofi and U.S. scientists, could offer a new way to treat or prevent HIV, following successful tests in monkeys. Plans are under way to try the so-called trispecific antibody in initial human trials before the end of 2018, ...

September 26, 2017
News  
Adverse Events of Raltegravir and Dolutegravir
1321  

Adverse Events of Raltegravir and Dolutegravir

To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. Methods: All antiretroviral therapy (ART)-naïve and ART-experienced HIV-infected individuals from the Swiss HIV Cohort Study who initiated raltegravir or dolutegravir between 2006 and 2015 were investigated concerning treatment modification within the first ...

September 26, 2017
News  
New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low-and middle-income countries at reduced price
1314  

New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low-and middle-income countries at reduced price

A breakthrough pricing agreement has been announced which will accelerate the availability of the first affordable, generic, single-pill HIV treatment regimen containing dolutegravir (DTG) to public sector purchasers in low- and middle-income countries (LMICs) at around US$75 per person, per year. The agreement is expected to ...

September 26, 2017
News  
Q&A: Treating older adults with HIV
1391  

Q&A: Treating older adults with HIV

One of the most vulnerable populations that is often overlooked when it comes to treating and preventing HIV is older adults. Prior research has demonstrated that stigma due to age is common among older Americans living with HIV, which can often intensify transmission of the virus. According to ...

September 20, 2017
News  
Vladimir Zhovtyak: Ending HIV/AIDS epidemic directly depends on treatment quality
1350  

Vladimir Zhovtyak: Ending HIV/AIDS epidemic directly depends on treatment quality

On September 6, in Poland, the ECUO held a working meeting jointly with the international experts, representatives of governmental institutions and activists of PLHIV communities, to discuss the new concept of access to innovative treatment. You can review the concept here. Without exaggeration, it is a landmark meeting that took place on the edge of two Europes: East and West. In West Europe, the epidemic is brought under control already, so HIV-infected people have an opportunity ...

September 12, 2017
Atherosclerotic Heart Attack Rate Is 20% Higher Among People With HIV
1193  

Atherosclerotic Heart Attack Rate Is 20% Higher Among People With HIV

HIV-positive U.S. residents in the large NA-ACCORD cohort had an atherosclerotic myocardial infarction (MI) rate 20% higher than people in a U.S. general-population cohort, newly published data reveal. This 29,169-person analysis also linked MI risk to lower CD4 count, higher viral load and a host ...

September 01, 2017
News  
Novel approach offers new insights into HIV’s lifecycle
1323  

Novel approach offers new insights into HIV’s lifecycle

Northwestern Medicine scientists have developed a novel method of tracking HIV infection, allowing the behavior of individual virions — infectious particles — to be connected to infectivity. The findings, published in Proceedings of the National Academy of Sciences, could help lead to the development of novel therapies for HIV ...

August 21, 2017
News  
HIV treatment: Strategies to reach the next 10 million patients
1467  

HIV treatment: Strategies to reach the next 10 million patients

PARIS — The last time the International AIDS Society Conference on HIV Science met in 2003, fewer than 2 million people globally were on HIV treatment. As the event returned to Paris this week, UNAIDS reported 19.5 million people are now taking antiretroviral therapy, or ART. The numbers put ...

July 31, 2017
News  
Another HIV vaccine efficacy trial will start this year
1400  

Another HIV vaccine efficacy trial will start this year

HVTN 705 vaccine study passes its “go” criteria: due to start this autumn A year ago, one of the biggest pieces of prevention news at the Durban International AIDS Conference was the announcement that a large HIV vaccine efficacy study would start in South Africa. HVTN 702, ...

July 26, 2017
AIDSmap  News